<DOC>
	<DOCNO>NCT01131091</DOCNO>
	<brief_summary>This Phase 1 , multicenter , open label , single dose study . A total 30 subject plan ( 5 group 6 subject . )</brief_summary>
	<brief_title>A Multicenter , Open Label , Single Dose Study Evaluate Effect Renal Insufficiency Pharmacokinetics SK 0403</brief_title>
	<detailed_description>This Phase 1 , multicenter , open label , single dose study . A total 30 subject plan ( 5 group 6 subject ) follow : Group A : Subjects ESRD receive hemodialysis treatment Group B : Subjects severe renal impairment Group C : Subjects moderate renal impairment Group D : Subjects mild renal impairment Group E : Healthy subject</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subject adult male female age 18 79 year , inclusive . All female subject ( 2 year postmenopausal document serum follicle stimulate hormone level &gt; 35 mIU/mL ) must negative serum pregnancy test Screening upon Check study clinic . Subject provide write informed consent studyspecific evaluation perform . Subject able willing comply protocol study procedure . Subject BMI &gt; 37 kg/m2 . Subject take prescribed systemic topical medication Subject donate 450 mL blood within 30 day start dose . Subject receive investigational drug within 30 day dose . Subject surgery gastrointestinal tract likely affect drug absorption . Subject clinically significant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>